Gain detailed insights into the trading activity of Congress members for Teladoc Health on our government trades page. Stay updated on how elected officials are investing in TDOC.

Teladoc Health - Government Trades

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Teladoc_Member_and_Child_on_Video_Visit-3

Equities

Mid Cap

News

Contracts

Movers

Tech

AMZN

KraneShares Trust KraneShares Man Buyout Beta Index ETF

BUYO

TDOC

Teladoc Health (NYSE: TDOC) partners with Amazon (NASDAQ: AMZN) to expand access to its chronic condition management programs. 

Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare

Hims & Hers Health, Inc. Class A Common Stock

HIMS


The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University

2 Telehealth Stocks That Could Gain from Trump&#39;s New FDA Pick

AAPL

NFLX

PTON

SPOT


The pandemic triggered a boom in stocks that accommodated physical isolation, convenient access from home, and fitness. Many of these stocks hit unbelievable highs during the lockdowns but collapsed just as hard in the

2 Former Pandemic Darlings Eyeing a Big 2025 Turnaround

Doctor Looking At Human Teeth X-ray

Earnings

Guidance

Health Care

After-Hours Center

Teladoc Health shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that topped analyst expectations.

Teladoc Health Q3 Earnings: Revenue Beat, EPS Beat, Shares Jump 10%

Small Cap

CDNA

IRMD

OMCL

TCMD

TSX:WELL

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space. 

1. Teladoc Health

Market Cap: $1.4 Billion

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

movers image

Intraday Update

Markets

ABNB

CURV

DCOM

GEVO

LIVN

SNBR

TALK

Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday

Pre-market: 5 titoli da monitorare oggi, 11 settembre 2024

HTLD

More Than $26M Bet On PBF Energy? Check Out These 3 Stocks Executives Are Buying

Robinhood Trade

Long Ideas

Sector ETFs

Specialty ETFs

Trading Ideas

ETFs

ARKK

AVGO

COIN

MSFT

NVDA

RBLX

ROKU

TSLA

ARKK&#39;s high-risk, high-reward strategy has led to a rollercoaster ride with no brakes, while QQQ&#39;s safer bet on established giants has seen consistent returns.

Why ARKK Stalled As QQQ Took Off: Harsh Lessons Over Past 5 Years

jim cramer shutter4

Media

ENVA

FTNT

GEHC

PANW

Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood&#39;s selling. He remains committed to Palo Alto Networks (PANW). He suggests traditional stock Wells Fargo (WFC) over Enova (ENVA). He declines playing Bentley Systems (BSY) due to high risk in enterprise software. GE Healthcare (GEHC) reports decent quarter.

&#39;I&#39;m Not Proud Of Myself&#39;: Jim Cramer Says He Bought &#39;Worst Of The Three&#39; GE Stocks

Medical,Technology,Concept.

Teladoc Health shares are trading lower Thursday after the company reported a second-quarter revenue miss and withdrew its full year financial outlook for its consolidated operations and BetterHealth segment.

What&#39;s Going On With Teladoc Health Stock After Earnings?

Teladoc Health Inc

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $11.86, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 9.51% increase from the previous average price target of $10.83.
<img src="https://www.benzinga.com/files/images/story/2025/1737752448_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Teladoc Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teladoc Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -5.2%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's ROE excels beyond industry benchmarks, reaching -2.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Teladoc Health Through The Eyes Of 7 Analysts

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $11 to $12.

Price Target

RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $12

Oppenheimer analyst Michael Wiederhorn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and lowers the price target from $14 to $12.

Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $12

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has risen 3.62% since its last report. The company recently reported that it has 23.53 million shares sold short, which is 17.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737060311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.32%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Teladoc Health's Recent Short Interest

Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are trading higher premarket on Tuesday. On Monday, the company disclosed a partnership with Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to broaden access to its chronic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42964279/teladoc-health-joins-amazons-health-benefits-connector-for-cardiometabolic-programs" rel="noreferrer noopener">condition management programs</a>.
Teladoc Health's chronic condition programs serve over 1 million active enrollees, utilizing connected devices, data-driven personalization, and expert coaching to promote lasting behavior changes and improve cardiometabolic health outcomes.
The company supports over 1 million enrollees in its chronic condition programs, using connected devices, personalized data, and expert coaching to improve cardiometabolic health.
Eligible Amazon customers can now discover and enroll in Teladoc's programs for diabetes, hypertension, pre-diabetes, and weight management through Amazon's Health Benefits Connector, previously known as Health Condition Programs.
Notably, over half of U.S. adults have a chronic condition, yet many face barriers to accessing digital health programs, the company said in the press release. Nearly 25% are unaware of their full health plan benefits.
Amazon's Health Benefits Connector addresses this by highlighting eligible benefits during product searches. Teladoc Health's participation reflects a joint effort to prioritize consumer-centric healthcare solutions.
Investors can gain exposure to the stock via KraneShares Trust KraneShares Man Buyout Beta Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUYO#NYSE">BUYO</a>).
<h2 class="wp-block-heading">Teladoc Health Stock Prediction for 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Teladoc Health, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Teladoc Health, the 200-day moving average sits at $10.07, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $9.7. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: TDOC shares are up 7.94% at $10.47 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42362891/2-telehealth-stocks-that-could-gain-from-trumps-new-fda-pick" target="_blank" rel="noreferrer noopener">2 Telehealth Stocks That Could Gain from Trump's New FDA Pick</a></li>
</ul>
Photo: courtesy of Teladoc.

General

Teladoc Health shares are trading higher after the company joined Amazon's Health Benefits Connector for its cardiometabolic programs.

Reported Earlier, Teladoc Health Expands Chronic Condition Program Enrollment Through Partnership With Amazon

Telehealth companies including Hims &amp; Hers, Sesame and Noom have flocked to Facebook and Instagram to promote their booming weight loss drugs.
But pressure from regulators concerned about consumers' health data privacy has prompted Meta Platforms to limit how advertisers target users with health-related ads, starting this month. That is upending weight loss campaigns in the middle of the New Year's resolution marketing season. And more broadly, marketers are scrambling to figure out exactly what kind of weight loss and other health-related products are affected, and trying out workarounds for the new rules.
<a href="https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom" title="https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom">https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom</a>
&nbsp;
&nbsp;
&nbsp;
&nbsp;

DRIO

'Meta Ad Changes Threaten Telehealth's Weight Loss Boom' - The Information

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 13.48% since its last report. The company recently reported that it has 22.71 million shares sold short, which is 17.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735671624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Teladoc Health's Recent Short Interest

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.0, a high estimate of $14.00, and a low estimate of $8.00. This current average reflects an increase of 18.41% from the previous average price target of $9.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1733320944_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teladoc Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.21%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 8 Analyst Insights On Teladoc Health

Piper Sandler analyst Jessica Tassan reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $11 to $13.

Reiteration

Piper Sandler Reiterates Overweight on Teladoc Health, Raises Price Target to $13

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 25.69 million shares sold short, which is 19.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Teladoc Health?

Teladoc Health Launches New AI-Capabilities To Enhance Virtual Sitter Solution To Improve Patient Safety

Goldman Sachs analyst David Roman initiates coverage on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy rating and announces Price Target of $14.

Initiation

Goldman Sachs Initiates Coverage On Teladoc Health with Buy Rating, Announces Price Target of $14

Deutsche Bank analyst George Hill maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $10 to $12.

Deutsche Bank Maintains Hold on Teladoc Health, Raises Price Target to $12

Barclays analyst Steve Valiquette maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $10 to $12.

Barclays Maintains Overweight on Teladoc Health, Raises Price Target to $12

TD Cowen analyst Charles Rhyee maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

TD Cowen Maintains Hold on Teladoc Health, Lowers Price Target to $8

WIIM

Teladoc Health shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results">topped analyst expectations</a>.
<ul>
<li>Q3 Revenue: $640.51 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $631.16 million</li>
</ul>
<ul>
<li>Q3 EPS: Loss of 19 cents, versus estimates for a loss of 27 cents</li>
</ul>
Total revenue was down 3% on a year-over-year basis. Integrated Care segment revenue was up 2% year-over-year, while BetterHelp segment revenue declined 10% year-over-year. U.S. revenue fell 6% year-over-year, while International revenue grew 15%.
Cash flow from operations totaled $110.2 million in the third quarter. The company said it generated $79 million in free cash flow during the quarter.
&#8220;As we close out 2024, we are moving with urgency and making changes to more effectively leverage our leadership position in the complex and dynamic markets we serve. There is more work ahead of us, and 2025 will be an important repositioning year. Our focus remains on delivering consistent performance and driving long-term shareholder value,&#8221; said Chuck Divita, CEO of Teladoc Health.
Guidance: Teladoc expects fourth-quarter Integrated Care segment revenue to be flat to up 2.5% in the fourth quarter. The company expects full-year Integrated Care segment revenue to grow in the low single digits to mid-single digits.
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were up 9.26 % in after-hours, trading at $9.68 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, &#8216;Strong Momentum&#8217; In AI</a>
Photo: Courtesy of Teladoc.

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. The company reported quarterly sales of $640.508 million which beat the analyst consensus estimate of $631.160 million by 1.48 percent. This is a 2.99 percent decrease over sales of $660.238 million the same period last year.

Earnings Beats

Teladoc Health Q3 2024 GAAP EPS $(0.19) Beats $(0.27) Estimate, Sales $640.508M Beat $631.160M Estimate

Press Releases

Teladoc Health Announces Employee Inducement Awards Under NYSE Rule 303A.08

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential

Teladoc Health to Participate in Upcoming Investor Conference

Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

Opinion

AI Healthcare Innovations: How They're Shaping the Future for Patients and Investors

Teladoc Health Joins Amazon's Health Benefits Connector for Cardiometabolic Programs

How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

ABSI

AVAI

BFLY

CLOV

HWAIF

MRNA

RHHBY

RXRX

TSX:AIDX

RBC Capital

Oppenheimer

Piper Sandler

Goldman Sachs

Deutsche Bank

Sale 35 Units Teladoc Health Inc Common; Capital Gain $900

Government Trades

Teladoc Health Inc

top performing TDOC trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga